Genetic Frontotemporal Dementia Initiative for Neurodevelopment
Launched by WESTERN UNIVERSITY · Mar 8, 2023
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
The Genetic Frontotemporal Dementia Initiative for Neurodevelopment is a study aimed at understanding Frontotemporal Dementia (FTD) in young people. Specifically, it focuses on family members aged 9 to 17 who have a close relative (like a parent or grandparent) with a genetic mutation linked to FTD. The main goal is to gather information that can help researchers learn more about this condition and its effects on children and teenagers.
To participate, young people must be between 9 and 16 years old and have a first or second-degree relative with a known FTD mutation. They need to have a parent or guardian who supports their involvement and can act as a study partner to provide information about their daily life. Participants will be followed until they turn 17 and may undergo various assessments, including possibly an MRI scan. It’s important to know that anyone with other serious brain issues or who doesn’t have a study partner may not be eligible for this study. The study is currently recruiting participants, and it offers a unique opportunity to contribute to important research on FTD and its impact on families.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Written informed consent must be obtained and documented (from the participant and their substitute decision maker). This can be obtained in person or remotely.
- • 2. Youths between the ages of 9 and 16 inclusive at time of enrollment, followed until age 17.
- • 3. Youths must have a 1st or 2nd degree biological relative who has participated (past or present) in the Genetic Frontotemporal Dementia Initiative (GENFI) study or with genetic FTD (i.e. a known mutation in biological parent or grandparent).
- • 4. Parent(s)/guardian deem appropriate to participate.
- • 5. Must have a study partner who can participate as required in the protocol (provide corroborative information). Study partner must have regular contact with the participant and must be parent/guardian of this participant.
- • 6. Must have age-appropriate awareness that FTD runs in their family as determined by local PI.
- Exclusion Criteria:
- • 1. Current structural brain abnormality affecting cognition or behaviour not thought to be possibly related to genetic FTD that would prevent completion of study assessments (such as brain tumor, stroke, hydrocephalus).
- • 2. Other concerns that participation in the study may not be in the best interest of the youth or parent, as raised by the participant's parent/guardian/primary care provider, local site PI or psychologist.
- • 3. Lack of study partner.
- • 4. For MRI: meeting any MRI incompatible criteria. Note: Participants may opt to decline MRI scans and complete the other measures.
About Western University
Western University is a leading research institution dedicated to advancing health sciences through innovative clinical trials. With a commitment to excellence in education and research, the university fosters collaboration among multidisciplinary teams to investigate novel therapeutic interventions and improve patient outcomes. Western University prioritizes ethical standards and regulatory compliance, ensuring that all clinical trials are conducted with the utmost integrity and respect for participant welfare. Through its robust infrastructure and expertise, Western University is at the forefront of translating scientific discoveries into impactful healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, Ontario, Canada
Patients applied
Trial Officials
Elizabeth Finger, MD
Principal Investigator
Western University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials